News
RDY
13.60
-2.79%
-0.39
Dr. Reddy’s Allots Equity Shares Under Employee Stock Options
TipRanks · 20h ago
BUZZ-Indian pharma stocks set for worst day in 2 years on Trump tariff woes
Reuters · 1d ago
Dr. Reddy’s Faces Tax Penalty from GST Authority
TipRanks · 3d ago
Dr. Reddy’s Laboratories to Engage in Key Investor Conferences
TipRanks · 3d ago
Weekly Report: what happened at RDY last week (0203-0207)?
Weekly Report · 5d ago
BUZZ-Henlius soars on deal with India's Dr. Reddy's Labs for myeloma drug
Reuters · 02/07 06:05
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Seeking Alpha · 02/06 17:07
Dr. Reddy’s Expands Oncology Portfolio with Henlius Partnership
TipRanks · 02/06 15:08
Dr. Reddy’s enters commercialization agreement with Henlius for HLX15
TipRanks · 02/06 13:01
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
Barchart · 02/06 06:51
Dr. Reddy’s Laboratories Schedules Investor Conference Participation
TipRanks · 02/05 12:27
Dr. Reddy’s Laboratories to Engage with Investors in Mumbai Conference
TipRanks · 02/04 14:02
Dr. Reddy’s Laboratories Engages with Investors in Upcoming Conferences
TipRanks · 02/04 14:01
Dr. Reddy’s Faces Tax Penalty with No Material Impact
TipRanks · 02/04 11:30
Dr. Reddy’s Faces GST Penalty, Evaluates Appeal
TipRanks · 02/03 11:27
Weekly Report: what happened at RDY last week (0127-0131)?
Weekly Report · 02/03 09:05
BUZZ-PREVIEW-India's Sun Pharma likely to see jump in Q3 profit
Reuters · 01/31 06:43
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Seeking Alpha · 01/30 22:03
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Seeking Alpha · 01/30 11:56
Dr. Reddy’s Laboratories Reports Strong Q3FY25 Financial Results
TipRanks · 01/29 18:01
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.